BTG International Germany GmbH

For more than 50 years, BTG has been at the forefront of medical innovation. We have helped to realize breakthroughs including Cephalosporin antibiotics, Interferon, Magnetic Resonance Imaging, recombinant Factor IX, the first non-plasma product for treating patients with haemophilia B, and abiraterone acetate, which has set a new standard of care for treating men with advanced prostate cancer.
Today, we are a growing international specialist healthcare company that is dedicated to improving the lives of people with cancer, vascular disorders and acute care needs. Our current portfolio includes industry-leading products that advance the treatment of people with liver cancer, blood clots and varicose veins, and of people who need antidotes if they are overexposed to certain medications or toxins.
We are committed to continuing to develop new products that meet the needs of specialist physicians and their patients. Partnership and innovation are at the heart of our approach. We work with medical practitioners to identify unmet needs. We invest in product innovation, physician-led exploratory studies and full-scale clinical trials: in 2013 we invested $68m, almost 18% of our revenue, in research and development.
We recognize our responsibilities to physicians, patients, payers and the communities where we operate. We invest in training and support programs, in studies that demonstrate the value of our products and in community outreach activities. In all our interactions, we are guided by strong core values. At BTG we believe in doing the right thing every time.


BTG International Germany GmbH

Industriestr. 19
63755 Alzenau
Klinik & Praxis
Sonstige Tätigkeitsfelder